• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Ono Pharma submits marketing approval of metyrosine in Japan

biospectrumasiaMay 03, 2018

Tag: Ono Pharmaceutical , metyrosine , Japan , Valeant

Japanese drugmaker Ono Pharmaceutical has submitted a new drug application for the approval of pheochromocytoma (PCC) treatment metyrosine (ONO-5371), a tyrosine hydroxylase inhibitor licensed from Canada’s Valeant Pharmaceuticals International in October 2013, in Japan. 

This application is based on a multicenter, open-label, non-comparative study and its accompanying continuous administration study, Phase I/II study (ONO-5371-02), in patients with the symptoms associated with catecholamine excess secretion of pheochromocytoma, conducted in Japan. 

Valeant markets metyrosine under the trade name of Demser in the indication of PCC

Register as Visitor to CPhI China 2018!

Previous:Samsung BioLogics’ stock slides after regulators claim accounting rules infraction

Next:India’s drug regulatory force conducts third round of raids on manufacturers

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Ono Pharma submits marketing approval of metyrosine in Japan | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Metyrosine

Metyrosine
Desiccant use Japanese Paper

Desiccant use Japanese Paper
American standard Japanese standard German standard gate valve

American standard Japanese standard German standard gate valve
Ceremonial Green Japanese Face Instant Greentea Grade Halal Pure Oem Japan Organic Matcha Tea Powder

Ceremonial Green Japanese Face Instant Greentea Grade Halal Pure Oem Japan Organic Matcha Tea Powder
Organic Ceremonial Green Japanese Face Instant Greentea Grade Halal Pure Oem Japan Matcha Tea Powder

Organic Ceremonial Green Japanese Face Instant Greentea Grade Halal Pure Oem Japan Matcha Tea Powder
Desiccants use Japanese papaer

Desiccants use Japanese papaer
Japanese Pagodatree Flower-bud

Japanese Pagodatree Flower-bud
Stephania japonica extract Japanese Stephania Root extract Tabellae Cepharanthini extract

Stephania japonica extract Japanese Stephania Root extract Tabellae Cepharanthini extract
Stephania japonica extract Japanese Stephania Root extract Tabellae Cepharanthini extract Rotundine

Stephania japonica extract Japanese Stephania Root extract Tabellae Cepharanthini extract Rotundine
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service